The aim of this study is to elucidate the efficacy and safety of pharmacoinvasive therapy by using prourokinase (prouk), a unique fibrin-specific agent, in patients with ST-segment elevation myocardial infarction (STEMI)
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
197
a bolus of 1.2 million IU and an infusion of 4.8 million IU in 60 min.
Shenyang Northern Hospital
Shenyang, Liaoning, China
angiographic parameters which can demonstrate the myocardium reperfusion, including TIMI flow grade (grade I-III), TIMI frame count (frame) and myocardial blush grade (MBG,grade 0-3).
Time frame: 90 minutes after prourokinase bolus
major adverse cardiac events [MACE, defined as the composite of all cause-death, reinfarction, revascularization (including target vessel and non-target vessel revascularizations), or rehospitalization due to new or worsening congestive heart failure]
Time frame: 12 month after enrollment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.